Targets › CACNB3
4 programs from 4 companies in 46 trials: 18 Phase 2, 13 Phase 4, 10 Phase 1, 5 Phase 3; Neurology, Oncology, Other; next expected readout Nov 2026.
Regulatory subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents. Increases CACNA1B peak calcium current and shifts the voltage dependencies of channel activation and inactivation (By similarity). (UniProt, P54284)
Open in Phaseline: the race on CACNB3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Viatris | Gabapentin Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 4 | Healthy; Tonsillitis; Dental Pain and Sensation Disorder; Pain, Postoperative … | Jan 2027 |
| University of Texas at Austin | Gabapentin Enacarbil Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 4 | Alzheimer Disease | – |
| Brainfarma Industria Química e Farmacêutica S/A | Pregabalin Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 3 | Diabetic Neuropathy; Shoulder Arthropathy; Pregabalin; Diabetic Pruritus … | Jun 2027 |
Alcohol Use Disorder (3) Head and Neck Squamous Cell Carcinoma (3) Pain, Postoperative (3) Alzheimer Disease (1) Diabetic Neuropathy (1) Shoulder Arthropathy (1) Pregabalin (1) Diabetic Pruritus (1) Rotator Cuff Repairs (1) Early-stage Breast Cancer (1) Painful Peripheral Neuropathy (1) Acute Kidney Injury (1)
small molecule (4)
University of Texas at Austin (1) Brainfarma Industria Química e Farmacêutica S/A (1) University of Pennsylvania (1) Viatris (1)
Ion channels (4) CACNB4 (4) CACNB2 (4) CACNB1 (4) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.